Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
gpASIT+ in grass pollen-induced allergic rhinoconjunctivitis
2017-002911-33Phase 3Terminated
- Sponsor
- ASIT Biotech
- Start
- Jun 2018
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC) and seasonal allergic rhinitis (SAR) comparing gpASIT+ with Placebo (2 arms). Primary endpoint: Average daily combined symptom and medication score during peak grass pollen season in Year 1. Started Jun 2018; status: terminated.
02
Drugs
gpASIT+
03
Conditions
allergic rhinoconjunctivitis (ARC)seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on 2017-002911-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002911-33.